A new test, developed by a Canadian specialty medical device company, appears to be a better predictor of colorectal cancer than the test currently being used. CA1-18, the company's two screening tests to detect early stage colorectal cancer. The year-long trial, conducted at the Wellesley site of St. Michael's Hospital in Toronto, involved 670 patients. The test is inexpensive and painless, does not require a blood test or stool sample, and requires no dietary restrictions prior to obtaining the sample. The data from the study is very comprehensive and our initial analysis supports the previously published scientific studies showing that ColorectAlert can identify individuals at risk for having early stage colorectal cancer.
Early detection allows for effective treatment that significantly improves patient outcomes.
Following the final analysis of the data from this study, we will submit the results to a scientific journal for publication. The results of the trial for CA1-18, a blood test for a protein marker, were less encouraging. IMI is a Canadian specialty medical device company, dedicated to developing innovative products for rapid and early detection of serious or life-threatening diseases. IMI is located in Toronto, Ontario. This news release contains forward-looking statements, which reflect the company's current expectation regarding future events.